Takeda Pharmaceutical Co. Ltd. ADR (TAK) News
Filter TAK News Items
TAK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TAK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TAK News From Around the Web
Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.
Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.Investors’ enthusiasm in early 2024 turned out to be misplaced, but corporate shake-ups, hints of inflation, and even trade issues could help the market now. |
Takeda's HYQVIA Approved in Japan To Treat ImmunodeficiencyTakeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase) for the treatment of patients with agammaglobulinemia or hypogammaglobulinemia. These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections. This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCI |
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or HypogammaglobulinemiaOSAKA, Japan & CAMBRIDGE, Mass., December 27, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary imm |
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship InitiativeTakeda Canada Inc. (Takeda) is proud to sponsor the Inaugural MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellows Initiative. This program aims to standardize training, organize networks, and implement Entrustable Professional Activities (EPAs) for advanced IBD fellows in Canada. |
Takeda Announces Subsidiary Liquidation and Merger CompletionTakeda Pharmaceutical Company ( (TAK) ) has shared an update. Takeda Pharmaceutical Company has submitted an extraordinary report detailing its decision to dissolve its specified subsidiary, Shire Pharmaceuticals International Unlimited Company, through liquidation. This move results in a significant change in the voting rights structure, marking the completion of a merger process where Takeda now holds no voting rights in the subsidiary. The liquidation process will follow local regulations, al |
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone |
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic AreasOSAKA, Japan & CAMBRIDGE, Mass., December 12, 2024--Takeda Spotlights High-Value, Late-Stage Pipeline of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas |
Novavax sells Czech plant to Novo; Relay licenses out a cancer drugNovo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy. |
Takeda licensed for anaemia therapy by Keros TherapeuticsTakeda will make an upfront payment of $200m to Keros. |
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: AnalystOn Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis. Also Read: Analyst Sees Keros Therapeutics |